Vesicoureteral reflux (VUR) is the most common urological disorder in children, affecting 1–2% of the pediatric population and 30–50% of children presenting with urinary tract infection (UTI). The association of VUR, UTI, and renal parenchymal damage is widely recognized. The introduction of endoscopic treatment of vesicoureteral reflux in the early 1980s was a radical departure from the standard long-term antibiotic prophylaxis and open surgical intervention in the management of VUR in children. Since the approval of dextranomer/hyaluronic acid (Deflux®) by the US Food and Drug Administration (FDA) in 2001 as an acceptable tissue augmenting substance for submucosal injection into the refluxing ureteral orifice, the 15 min day care endoscopic procedure has gained worldwide popularity in the management of VUR in children. Over the years, multiple studies have demonstrated safety and long-term efficacy of this minimally invasive outpatient procedure.